The Phase II clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).
Wellbeing Digital Sciences’ wholly owned subsidiary KGK Sciences, has entered into a research services agreement with Halucenex Life Sciences, a psychedelic subsidiary of Creso Pharma.
CEO of Wellbeing and KGK, Najla Guthrie, commented: “We are thrilled to be working with Halucenex for their planned phase II clinical trials to test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).
“Over the past 25 years, we have successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets.
“This marks an important step in moving the industry that much closer to creating alternative medicines for a growing population base.”
Under the research and services agreement with Halucenex, KGK will perform research services, including the development of the clinical trial protocol, preparations towards the Phase II clinical trials, data management and validation, statistical analysis and drafting of the final report.
CEO and Founder of Halucenex, Bill Flemming, commented: “KGK is a leading contract research organization (CRO), offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries.
“We are confident that KGK’s role will enable us to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions.”
[activecampaign form=52]
